SiVEC Biotechnologies

Tissue Specific Nucleic Acid Delivery System for Therapeutic and Vaccine Development

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Fort Collins, CO, USA
  • Currency USD
  • Founded April 2016
  • Employees 2
  • Incorporation Type LLC
  • Website sivecbiotechnologies.com

Company Summary

For companies developing Nucleic Acid therapies (NA) who are dissatisfied with existing systems, SiVEC uses engineered nonpathogenic bacteria for targeted delivery of large TNA payloads. As the tech matures, a milestone based commercial licensing strategy will be followed. Targets include influenza, cancer, genetic disorders and next gen vaccines. SiVEC is receiving NIH funding totaling $3.3M for a NA therapy for flu.

Team

  • Lyndsey Linke
    CEO

    SiVEC Biotechnologies is led by Lyndsey Linke, Ph.D., M.E., (CEO and co-founder). Lyndsey has secured over $3.5M in grants & sponsored research, has over 15 years’ R&D experience with novel therapeutics, antivirals and is lead inventor on 12 issued or pending patents. Lyndsey is a US Olympic Trials qualifying swimmer and is a 6 time US National Masters swimming champion.

  • Darcy Mora
    VP of Operations

    Darcy has over 10 years’ experience with infectious disease research, she has served as a lead developer for more than 10 global wildlife vaccines and is an inventor on 6 issued or pending patents.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free